The beam dump facility (BDF) is a project for a new facility at CERN dedicated to high intensity beam dump and fixed target experiments. Currently in its design phase, the first aim of the facility ...is to search for light dark matter and hidden sector models with the Search for Hidden Particles (SHiP) experiment. At the core of the facility sits a dense target/dump, whose function is to absorb safely the400GeV/cSuper Proton Synchrotron (SPS) beam and to maximize the production of charm and beauty mesons. An average power of 300 kW will be deposited on the target, which will be subjected to unprecedented conditions in terms of temperature, structural loads and irradiation. In order to provide a representative validation of the target design, a prototype target has been designed, manufactured, and tested under the SPS fixed-target proton beam during 2018, up to an average beam power of 50 kW, corresponding to 350 kJ per pulse. The present contribution details the target prototype design and experimental setup, as well as a first evaluation of the measurements performed during beam irradiation. The analysis of the collected data suggests that a representative reproduction of the operational conditions of the beam dump facility target was achieved during the prototype tests, which will be complemented by a postirradiation examination campaign during 2020.
The Super Proton Synchrotron (SPS) is the last stage in the injector chain for CERN's Large Hadron Collider, and it also provides proton and ion beams for several fixed-target experiments. The SPS ...has been in operation since 1976, and it has been upgraded over the years. For the SPS to operate safely, its internal beam dump must be able to repeatedly absorb the energy of the circulating beams without sustaining damage that would affect its function. The latest upgrades of the SPS led to the requirement for its beam dump to absorb proton beams with a momentum spectrum from 14 to 450~GeV/\(c\) and an average beam power up to \(\sim\)270~kW. This paper presents the technical details of a new design of SPS beam dump that was installed in one of the long straight sections of the SPS during the 2019--2020 shutdown of CERN's accelerator complex. This new beam dump has been in operation since May 2021, and it is foreseen that it will operate with a lifetime of 20~years. The key challenges in the design of the beam dump were linked to the high levels of thermal energy to be dissipated -- to avoid overheating and damage to the beam dump itself -- and high induced levels of radiation, which have implications for personnel access to monitor the beam dump and repair any problems occurring during operation. The design process therefore included extensive thermomechanical finite-element simulations of the beam-dump core and its cooling system's response to normal operation and worst-case scenarios for beam dumping. To ensure high thermal conductivity between the beam-dump core and its water-cooling system, hot isostatic pressing techniques were used in its manufacturing process. A comprehensive set of instrumentation was installed in the beam dump to monitor it during operation and to cross-check the numerical models with operational feedback.
The Beam Dump Facility (BDF) is a project for a new facility at CERN dedicated to high intensity beam dump and fixed target experiments. Currently in its design phase, the first aim of the facility ...is to search for Light Dark Matter and Hidden Sector models with the Search for Hidden Particles (SHiP) experiment. At the core of the facility sits a dense target/dump, whose function is to absorb safely the 400 GeV/c Super Proton Synchrotron (SPS) beam and to maximize the production of charm and beauty mesons. An average power of 300 kW will be deposited on the target, which will be subjected to unprecedented conditions in terms of temperature, structural loads and irradiation. In order to provide a representative validation of the target design, a prototype target has been designed, manufactured and tested under the SPS fixed-target proton beam during 2018, up to an average beam power of 50 kW, corresponding to 350 kJ per pulse. The present contribution details the target prototype design and experimental setup, as well as a first evaluation of the measurements performed during beam irradiation. The analysis of the collected data suggests that a representative reproduction of the operational conditions of the Beam Dump Facility target was achieved during the prototype tests, which will be complemented by a Post Irradiation Examination campaign during 2020.
•High-calorie, high-protein, peptide-based oral nutritional supplements have demonstrated to reduce gastrointestinal symptoms and improve nutritional status•High-calorie, high-protein, peptide-based ...oral nutritional supplement compliance in patients with cancer has no significant difference with patients without cancer•Sex and initial nutritional status were factors affecting compliance
Compliance in outpatients with gastrointestinal (GI) malabsorption is key in nutritional treatment. The objective of this study was to assess compliance in patients with GI impairment and malnutrition taking a high-calorie, high-protein, peptide-based oral nutritional supplement (ONS-PBD).
A prospective, multicenter, observational study was conducted in 19 medical sites in Spain where ONS-PBD were prescribed as standard of care. Patients consumed ONS-PBD daily for 12 wk. Compliance was calculated as the percentage consumed of the prescribed amount of ONS per day.
A total of 90 adult patients were included in the study, of whom 64 completed the 12-wk regimine. Mean compliance was 78.8% ± 24.5%. Risk of malnutrition decreased in 56.3% of patients at 12 wk, as measured with the malnutrition universal screening tool. A reduction in abdominal pain was observed and stool consistency improved, with a mean of 54.7% and 27.5%, respectively. Improvements in quality of life and a decrease in percentage of patients with severe functional impairment were observed.
These data show that ONS-PBD compliance in malnourished patients with GI symptoms is high, reducing GI symptoms and improving patients’ nutritional status.
ObjectivesMycophenolate mofetil (MMF) and azathioprine (AZA) are immunomodulatory treatments in interstitial lung disease (ILD). This systematic review aimed to evaluate the efficacy of MMF or AZA on ...pulmonary function in ILD.DesignPopulation included any ILD diagnosis, intervention included MMF or AZA treatment, outcome was delta change from baseline in per cent predicted forced vital capacity (%FVC) and gas transfer (diffusion lung capacity of carbon monoxide, %DLco). The primary endpoint compared outcomes relative to placebo comparator, the secondary endpoint assessed outcomes in treated groups only.Eligibility criteriaRandomised controlled trials (RCTs) and prospective observational studies were included. No language restrictions were applied. Retrospective studies and studies with high-dose concomitant steroids were excluded.Data synthesisThe systematic search was performed on 9 May. Meta-analyses according to drug and outcome were specified with random effects, I2 evaluated heterogeneity and Grading of Recommendations, Assessment, Development and Evaluation evaluated certainty of evidence. Primary endpoint analysis was restricted to RCT design, secondary endpoint included subgroup analysis according to prospective observational or RCT design.ResultsA total of 2831 publications were screened, 12 were suitable for quantitative synthesis. Three MMF RCTs were included with no significant effect on the primary endpoints (%FVC 2.94, 95% CI −4.00 to 9.88, I2=79.3%; %DLco −2.03, 95% CI −4.38 to 0.32, I2=0.0%). An overall 2.03% change from baseline in %FVC (95% CI 0.65 to 3.42, I2=0.0%) was observed in MMF, and RCT subgroup summary estimated a 4.42% change from baseline in %DLCO (95% CI 2.05 to 6.79, I2=0.0%). AZA studies were limited. All estimates were considered very low certainty evidence.ConclusionsThere were limited RCTs of MMF or AZA and their benefit in ILD was of very low certainty. MMF may support preservation of pulmonary function, yet confidence in the effect was weak. To support high certainty evidence, RCTs should be designed to directly assess MMF efficacy in ILD.PROSPERO registration numberCRD42023423223.
A phase I clinical trial was performed to examine the safety and immunogenicity of a multi-epitope polypeptide comprising the central 15 amino acids of the V3 loop from six HIV-1 isolates. This ...protein called TAB9 was emulsified in Montanide ISA720 (Seppic, Paris) and administered intramuscularly at doses of 0, 0.2 and 1 mg to 24 healthy, HIV-1 seronegative adult males. Three immunisations were given at months 0, 1 and 6 in a randomised, double blind, placebo controlled clinical trial. The placebo was generally well tolerated. However, severe local reactions were observed in TAB9 vaccinated subjects after the second and third inoculations. Seven out of eight volunteers from the lower dose group showed moderate or severe local inflammation, while four out of eight subjects from the higher dose group developed granulomas and sterile abscesses. In general, the reactogenicity depended on the number of inoculations given and the dose of TAB9. Both doses were immunogenic, all immunised volunteers seroconverted and antibodies were broadly reactive against the V3 peptides included in the protein. All vaccine's sera reacted against gp120 in Western blot and 50% of them also neutralised at least one out of five laboratory isolates tested. No differences between doses were found. Anti TAB9 lymphoproliferative responses were observed, being more intense in the high dose group. Due to the strong local reactions that were found in this study, a change in the formulation will be required for further trials with this vaccine candidate in humans.
PDF
